When was Syngene founded?

Syngene was founded in 1993 and raised its 1st funding round 19 years after it was founded.

Where is Syngene located?

Syngene is headquartered in Bengaluru, India. It is registered at Biocon SEZ, Biocon Park,Plot.No.2 & 3, Bommasandra Indst. Area IV Phase, Jigani Link Rd, Bo, mmasandra, Bangalore, Karnataka, India, 560099.

How many employees does Syngene have?

As of Mar 31, 2026, the latest employee count at Syngene is 6600.

Is Syngene a funded company?

Syngene is a funded company, having raised a total of $85.9M across 3 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Oct 2012.

When was the latest funding round of Syngene?

Syngene's latest funding was a $***** Post IPO round on Feb 02, 2023, with participation from 6 investors. Its primary sector is Biopharma Outsourcing. In India, the Biopharma Outsourcing sector has seen $349M in funding in 2026 to date.

What is the annual revenue of Syngene?

Annual revenue of Syngene is more than ₹1,000 Cr as on Mar 31, 2026

Syngene - 2026 Company Profile, Team, Funding & Financials

Syngene is a public company based in Bengaluru (India), founded in 1993. It operates as a Provider of contract research and manufacturing services for both small molecules and biologics. Syngene has raised $85.9M in funding from True North.

Company Details

Provider of contract research and manufacturing services for both small molecules and biologics. Its discovery services cover multiple domains across small molecules, large molecules, antibody-drug conjugates (ADC) and oligonucleotides. Its biological services include recombinant DNA engineering, cell line development, hybridoma technology, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. Its synthetic chemistry and medicinal chemistry services can be accessed with emphasis either on chemistry discipline capabilities or more comprehensively along with DMPK and biological support.

Website: www.syngeneintl.com/
Social
Email ID: *****@syngeneintl.com
Part Of
Registered Address: Biocon SEZ, Biocon Park,Plot.No.2 & 3, Bommasandra Indst. Area IV Phase, Jigani Link Rd, Bo, mmasandra, Bangalore, Karnataka, India, 560099

Key Metrics

Founded Year

1993

Location

Bengaluru, India

Stage

Public

Total Funding

$85.9M in 3 rounds

Latest Funding Round

Post IPO, Feb 02, 2023, $*****

Investors

True North & 10 more

Annual Revenue

₹1,000+ Cr as on Mar 31, 2026

Employee Count

6,600 as on Mar 31, 2026

Investment & Acquisitions

Immuneel

Similar Companies

WuXi AppTec & 1205 more

Exit Details

Public

View Syngene's full profile

Syngene is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
SYNGENE SCIENTIFIC SOLUTIONS LIMITED CIN: U73200KA2022PLC164804 , India, Active	Aug 10, 2022	₹100 - ₹500 Cr (As on Mar 31, 2025)	-
SYNGENE INTERNATIONAL LIMITED CIN: L85110KA1993PLC014937 , India, Active	Nov 18, 1993	₹1,000+ Cr (As on Mar 31, 2026)	5545 (As on Apr 01, 2026)

Syngene got listed on Aug 11, 2015.

Click here to take a look at Syngene's IPO in detail

Syngene has raised a total funding of $85.9M over 3 rounds. Its first funding round was on Oct 2012. Its latest funding round was a Post IPO round on Feb 02, 2023 for $*****. 6 investors participated in its latest round. Syngene has 11 institutional investors.

Here is the list of recent funding rounds of Syngene:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 02, 2023	6224218	Post IPO	7227677	3594075	1671402	5864520
Sep 18, 2014	5569347	PE	5038060	9807609	3422690	5891771
Oct 2012	3196384	PE	9239268	5932131	1504044	GE Capital

Access funding benchmarks and valuations. Sign up today!

View details of Syngene's funding rounds and investors

Syngene's Board of Directors

Syngene's board has 10 active members. Jonathan Hunt is part of team and Kiran Mazumdar Shaw, Vinita Bali, Sharmila Abhay Karve, Sibaji Biswas, Vijay Kumar Kuchroo, Kush M Parmar, Catherine Patricia Rosenberg, Nilanjan Roy and Manja Hermina Elisabeth Maria Boerman are independent board members.

Here is the list of Syngene's board of directors:

Name	Type	Representing	Status	Duration
zup{asz	Team	-	Current	2y 7m
Kiran Mazumdar Shaw	Independent board member	-	Current	32y 11m
{endwgz	Independent board member	-	Current	6y 6m
uzj{hdv	Independent board member	-	Current	8y 2m
f{y{wil	Independent board member	-	Current	7y 5m
kjaljah	Independent board member	-	Current	5y 3m
teilxbu	Independent board member	-	Current	6y 4m
ulxxtwr	Independent board member	-	Current	8y 5m
ilon{jk	Independent board member	-	Current	7y 7m
gqe{kpf	Independent board member	-	Current	9y 9m

Syngene's employee count trend

Syngene has 6,600 employees as of Mar 26. Here is Syngene's employee count trend over the years:

Uncover Syngene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

SYNGENE INTERNATIONAL LIMITED, the legal entity associated with Syngene, generated more than ₹1,000 Cr in revenue for the financial year ending on Mar 31, 2026. The revenue of SYNGENE INTERNATIONAL LIMITED has a compounded annual growth rate (CAGR) of 3% in the last 1 year.

Financial Statement Summary

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22
Income Statement
Revenue	6219	4818	5063	7428	2807
Total Sales	9058	6278	9325	4137	9928
Total Expenses	3322	8541	5546	8164	3611
Operating Expenses	5610	7127	9155	9870	3174
Employee Expenses	1114	3111	8683	6469	8599
Marketing Expenses	5361	4967	3256	7321	3147
Operating Income (EBIT)	1222	8324	5154	1903	6814
Interest Expenses	6236	7953	4452	6117	2546
Expenses from other activities	1404	2430	9375	6058	5797
EBITDA	7235	5728	1701	3978	2158
Taxes	3567	4902	9676	1959	3193
Net Profit	5102	9208	2821	2817	5867
Balance Sheet
Assets	7987	1087	1851	7970	4792
Cash Equivalent	1078	6508	2110	8573	1603
Accounts Receivables	5534	9143	9479	7930	5472
Inventory	6207	8014	2071	5324	2781
Liabilities	2807	2848	9369	3941	3028
Total Debt	2911	9876	6789	4050	4666
Accounts Payable	2022	1020	1396	3165	2588
Equities	4669	9265	9641	8379	2817
Cashflow Statement
Cash from Operating activities	8753	2154	1092	1232	9247
Cash from Investing activities	8699	7798	4958	2690	5025
Net cash from Financing activities	3582	2245	6539	2443	8012